NASDAQ false 0001095981 0001095981 2024-05-31 2024-05-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 31, 2024

 

 

PLUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-34375   33-0827593

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

4200 Marathon Blvd., Suite 200

Austin, Texas 78756

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (737) 255-7194

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol

 

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   PSTV   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 


Item 1.01

Entry into a Material Definitive Agreement.

On May 31, 2024, Plus Therapeutics, Inc. (the “Company”) drew $3.3 million on its existing margin loan facility (the “Pershing Credit Facility”) with Pershing LLC (“Pershing”), an affiliate of The Bank of New York Mellon Corporation. The Company drew the funds to make the repayments described under Item 1.02 below.

Borrowings under the Pershing Credit Facility bear interest at the target interest rate set by the Federal Open Market Committee, subject to a floor of 5.5%, plus a spread of 1.75% and applicable fees of 0.5%, subject to a maximum interest rate of the then applicable Prime Rate as published in The Wall Street Journal plus 3.0%. Interest payments thereunder are calculated on a monthly basis and, unless paid, are added to the outstanding balance under the Pershing Credit Facility. The proceeds under the Pershing Credit Facility are available for working capital needs and other general corporate purposes. The Pershing Credit Facility includes certain covenants and restrictions, which may require the Company, on an on-going basis, to deposit additional funds or marketable securities in order to maintain the line of credit extended by Pershing.

The available credit line limit under the Pershing Credit Facility fluctuates based on the Company’s request for extensions of credit from time to time, subject to the value of the collateralized marketable securities that the Company holds with Pershing, provided that the amount available to draw under the Pershing Credit Facility cannot exceed 91.5% of the value of the Company’s collateralized marketable securities deposited with Pershing (the “Collateral”). Depending on the value of the Collateral that the Company holds with Pershing, Pershing may require the Company, on an on-going basis, to deposit additional funds or marketable securities in order to restore the level of the Collateral to an acceptable level. The amounts borrowed under the Pershing Credit Facility are due on demand.

The Pershing Credit Facility is secured by a general lien and security interest in the Company’s Collateral held in its account with Pershing. Upon certain customary events of default, Pershing has the right, in its discretion, to liquidate, withdraw or sell all or any part of the Collateral and apply the proceeds to the amounts outstanding under the Pershing Credit Facility. The Pershing Credit Facility is also subject to certain customary terms and conditions.

The foregoing description of the Pershing Credit Facility does not purport to be complete and is qualified in its entirety by reference to the full and complete terms of the Pershing Credit Facility loan documents, copies of which are filed hereby as Exhibits 10.1, 10.2 and 10.3 and are incorporated herein by reference.

 

Item 1.02

Termination of a Material Definitive Agreement.

On May 29, 2015, the Company entered into a Loan and Security Agreement, that was subsequently amended, with Oxford Finance, LLC (“Oxford”) (the “Oxford Term Loan”). On June 3, 2024, following the drawing of $3.3 million on the Pershing Credit Facility on May 31, 2024, the Company repaid the Oxford Term Loan in full, a payment amount that totaled approximately $3.3 million, which included both the balance of outstanding principal and interest and the final payment fee due. The repayment in full of the Oxford Term Loan terminated Oxford’s security interest in the Company’s existing and after-acquired assets, as well as all other certain restrictions and covenants under the Oxford Term Loan.


Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated in this Item 2.03 by reference.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit

  

Description

10.1    Lending Agreement, dated April 5, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC
10.2    Loan Interest Rate Form, dated May 24, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC
10.3    Extension of Credit, dated May 29, 2024, by and between Plus Therapeutics, Inc. and Pershing LLC
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    PLUS THERAPEUTICS, INC.
Date: June 4, 2024     By:  

/s/ Andrew Sims

    Name:   Andrew Sims
    Title:   Chief Financial Officer

Exhibit 10.1

LoanAdvanceTM Lending Agreement

 

 

 

KEEP A COPY FOR YOUR RECORDS. This is your LoanAdvance Lending Agreement with Pershing LLC (“Pershing”).

 

TO: Pershing LLC

In consideration of your accepting and carrying for the undersigned one or more accounts introduced to you by my broker, bank, or other introducing firm (“Introducing Firm”), which Introducing Firm is intended to have the benefit and is a third party beneficiary of this agreement, the undersigned agrees as follows:

Role of Pershing

I understand that Pershing is the carrier of the accounts of the undersigned as clearing broker pursuant to a clearing agreement with the Introducing Firm. Until receipt from the undersigned of written notice to the contrary, Pershing may accept from the Introducing Firm, without inquiry or investigation, instructions concerning said accounts. Notices to the undersigned concerning LoanAdvance loan requirements or other matters related to the undersigned’s accounts usually will go through the undersigned’s Introducing Firm although direct notice to the undersigned with duplicate notice to the undersigned’s Introducing Firm may occur if market conditions, time constraints, or other circumstances require it. Pershing shall not be responsible or liable for any acts or omissions of the Introducing Firm or its employees. I understand that Pershing provides no investment advice, nor does Pershing give advice or offer any opinion with respect to the suitability of any transaction or order. I understand that my Introducing Firm is not acting as the agent of Pershing and I agree that I will in no way hold Pershing, its other divisions, and its officers, directors, agents, or affiliates liable for any trading losses incurred by me.

1. Applicable Rules and Regulations

All transactions for the undersigned shall be subject to the constitution, rules, regulations, customs, and usages of the exchange or market and its clearing house, if any, where executed by Pershing or its agents, including its subsidiaries and affiliates.

2. Definitions

For purposes of this agreement “securities, commodities, and other property,” as used herein shall include, but not be limited to money, securities, and commodities of every kind and nature and all contracts and options relating thereto, whether for present or future delivery.

3. Lien

All securities, commodities, and other property of the undersigned, which Pershing may at any time be carrying for the undersigned, or which may at any time be in Pershing’s possession or under Pershing’s control, shall be subject to a general lien and security interest in Pershing’s favor for the discharge of all of the undersigned’s indebtedness and other obligations to Pershing, without regard to Pershing having made any advances in connection with such securities and other property and without regard to the number of accounts the undersigned may have with Pershing. In enforcing its lien, Pershing shall have the discretion to determine which securities and property are to be sold and which contracts are to be closed. Securities and other property held in the undersigned’s retirement account(s) maintained by Pershing, which may include IRAs or qualified plans, are not subject to this general lien and such securities or other property may only be used to satisfy the undersigned’s indebtedness or other obligations to your Introducing Firm and/or Pershing related to the undersigned’s retirement account(s).

4. Liquidation

If, in its discretion, Pershing considers it necessary for its protection to require additional collateral, or in the event that a petition in bankruptcy is filed, or an appointment of a receiver is filed by or against the undersigned, or an attachment is levied against the accounts of the undersigned, or in the event of the death of the undersigned, Pershing shall have the right to

sell any or all securities, commodities, and other property in the accounts of the undersigned with Pershing, whether carried individually or jointly with others, to buy any or all securities, commodities, and other property which may be short in such accounts, to cancel any open orders, and to close any or all outstanding contracts, all without demand for collateral or additional collateral, notice of sale or purchase, or other notice or advertisement. Any such sales or purchases may be made at Pershing’s discretion on any exchange or other market where such business is usually transacted, or at public auction or private sale, and Pershing may be the purchaser for its own account. It being understood that a prior demand, or call, or prior notice of the time and place of such sale or purchase shall not be considered a waiver of Pershing’s right to sell or buy without demand or notice. To the extent permitted by law, the undersigned waive compliance with the provisions of Section 202 of the New York Lien Law, including notice of sale, advertisement and related provisions of Article 9 of the New York Lien Law.

5. Payment of Indebtedness Upon Demand and Liability for Costs of Collection

The undersigned shall at all times be liable for the payment upon demand of any debit balance or other obligations owing in any of the accounts of the undersigned with Pershing, and the undersigned shall be liable to Pershing for any deficiency remaining in any such accounts in the event of the liquidation thereof, in whole or in part, by Pershing or by the undersigned; and, the undersigned shall make payments of such obligations and indebtedness upon demand. The reasonable cost and expense of collection of the debit balance, recovery of securities, and any unpaid deficiency in the accounts of the undersigned with Pershing, including, but not limited to attorney’s fees, incurred and payable or paid by Pershing, shall be payable to Pershing by the undersigned.

6. Pledge of Securities

All securities, commodities, and other property now or hereafter held, carried, or maintained by Pershing in its possession in any of the accounts of the undersigned may be pledged, repledged, hypothecated or rehypothecated by Pershing from time to time, without notice to the undersigned, either separately or in common with other such securities, commodities, and other property for any amount due in the accounts of the undersigned, or for any greater amount, and Pershing may do so without retaining into its possession or control for delivery, a like amount of similar securities, commodities, or other property.

7. Credit Charges

The monthly debit balances or adjusted balances in the accounts of the undersigned with Pershing shall be charged, in accordance with its practice, with interest at a rate permitted by the laws of the State of New York, as further described in this agreement. It is understood that the interest charge made to the undersigned’s account at the close of a charge period will be added to the opening balance for the next charge period unless paid.

8. LoanAdvance Account

LoanAdvance enables the undersigned to obtain a loan secured by the securities, commodities, and other property now or hereafter held, carried, or maintained by the undersigned in Pershing’s possession. Any such loan will be made in a special LoanAdvance account that is not a margin account. Pershing will establish in the LoanAdvance account, on behalf of the undersigned, a line of credit through which the undersigned may obtain the loan. Each loan disbursement will appear as a debit balance on the monthly or quarterly statement of the account. The undersigned agrees that Pershing will charge interest on the debit balance and that Pershing will require the undersigned to maintain securities, cash, or

 

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 1 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT


LoanAdvanceTM Lending Agreement

 

 

 

other property to secure repayment of funds advanced and interest due in accordance with procedures herein. The loan may be obtained by any one of the undersigned with the understanding that all of the undersigned will be liable, jointly and severally, for repayment of the loan and interest thereon. The loan may be obtained up to a credit limit that Pershing will establish. The credit limit may fluctuate from time to time, based on the value of the collateral held in the brokerage or managed account(s) being used as collateral and Pershing’s current collateral requirements. In addition, interest and fees assessed to the LoanAdvance account are considered an extension of the loan and are taken into account when determining the available credit limit.

9. Limitations of LoanAdvance

LoanAdvance loans may be used for any lawful purpose other than to purchase, carry, or trade securities, to meet margin calls relating to securities purchases, or for reducing or retiring indebtedness incurred to purchase, carry, or trade securities. The client is permitted frequent asset substitutions, provided that the equity and collateral remains at an acceptable level. Note: Mutual fund purchases and sales must be within the same family of funds in order to get immediate release on collateral.

NOTE: In addition, when the collateral and loan are held within the same brokerage account, only occasional collateral substitutions that occur on the same day are permitted, and transactions cannot increase the client’s loan balance.

10. Interest Rates

Your Base Rate, as defined in the interest rate disclosure, will change without prior notice. When your Base Rate changes during an interest period, interest will be calculated according to the number of days each rate is in effect during that period. Regardless of the underlying Base Rate, interest charged in any credit extended in a LoanAdvance account may never exceed a rate equal to 3 percentage points above the Prime Rate as published in The Wall Street Journal.

11. Interest Period

The interest period begins on the 20th of each month and ends on the 19th of the following month. Accordingly, the interest charges for the period as shown on the monthly or quarterly statement are based only on the daily net debit balances for the interest period.

12. Method of Interest Computation

At the close of each interest period during which credit was extended in a LoanAdvance account, an interest charge is computed by multiplying the average daily debit balance by the applicable schedule rate, and then by the number of days during which a debit balance was outstanding, and finally dividing by 360. If there has been a change in the Base Rate, separate computations will be made with respect to each rate of charge for the appropriate number of days at each rate during the interest period. The interest charge for credit made to a LoanAdvance account at the close of the interest period is added to the opening debit balance for the next interest period unless paid.

13. General Collateral Policies

The amount of credit that may be extended (the credit limit) by Pershing will be set from time to time. If the market value of securities in a brokerage or managed account(s) being used as collateral declines, Pershing may require the deposit of additional collateral. The equity in a brokerage or managed account(s) being used as collateral is the current market value of securities and cash deposited as security less the amount owed to Pershing for credit extended. For information with respect to general collateral maintenance policy as to stocks, municipal bonds, corporate bonds, listed U.S. Treasury notes and bonds, mutual funds, and other securities, as well as information about the eligibility of particular securities for LoanAdvance purposes, the undersigned should contact the Introducing Firm.

Pershing reserves the right, at its discretion, to require the deposit of additional collateral and to set collateral requirements at a higher or lower amount with respect to particular accounts or classes of accounts, as Pershing deems necessary. In making this determination, Pershing may take into account various factors including but not limited to

(i) issues as to the undersigned’s securities such as, among others, the liquidity of a position and concentrations of securities in an account,

(ii) considerations as to the undersigned’s status, including but not limited to a decline in creditworthiness, (iii) the size of the account, (iv) the general condition of the market, (v) considerations as to the ability of Pershing to obtain financing, and (vi) regulatory interpretations or guidance. If the undersigned fails to meet a call for additional collateral in a timely manner, some or all of the positions held by the undersigned may be liquidated.

14. Deposits of Collateral, Lien on Accounts, and Liquidation

In the event that additional collateral is requested due to a downturn in the market and/or the decline in value of your securities held as collateral, the undersigned may be required to deposit funds or acceptable securities into the brokerage or managed account(s) in order to restore the level of collateral to an acceptable level. If satisfactory collateral is not promptly deposited after a request is made, Pershing may, at its discretion, liquidate securities held in any of the undersigned accounts. If securities are liquidated based on the need for additional collateral, the undersigned understands that there may be tax implications associated with the liquidation, such as capital gains tax, depending on your cost basis in the collateral and other factors affecting your tax status.

15. Credit Investigation, Negative Credit Report

The undersigned authorizes Pershing to exchange credit information about the undersigned and the account with others. As required by law, the undersigned is notified that any negative credit report that appears on his or her credit records may be submitted to a credit reporting agency if the undersigned fails to fulfill the terms of the credit obligations. Pershing may request a credit report on the undersigned. Upon request by the undersigned, Pershing will state the name and address of the consumer reporting agency that furnished it. If Pershing extends, updates, reviews, or renews credit to the undersigned, Pershing may request a new credit report without notifying the undersigned. Pershing may also request a new credit report in accordance with its normal account maintenance procedures without notifying the undersigned.

16. Communications

Communications may be sent to the undersigned at the current address of the undersigned, which is on file at Pershing’s office, or at such other address as the undersigned may hereafter give Pershing in writing, or through the Introducing Firm, and all communications, so sent, whether by mail, telegraph, messenger, or otherwise, shall be deemed given to the undersigned personally, whether actually received or not.

17. Scope and Transferability

This agreement shall cover individually and collectively all accounts that the undersigned may open or reopen with Pershing for the purpose of obtaining a LoanAdvanceloan , and shall inure to the benefit of its successors and assigns, whether by merger, consolidation, or otherwise, and Pershing may transfer the accounts of the undersigned to its successors and assigns, and this agreement shall be binding upon the heirs, executors, administrators, successors, and assigns of the undersigned.

18. No Professional Advice

The undersigned acknowledges that Pershing will not provide the undersigned with any investment, legal, tax, or accounting advice, that its employees are not authorized to give any such advice, and that the undersigned will not solicit or rely upon any such advice from Pershing or its employees whether in connection with transactions in or for any of the accounts of the undersigned or otherwise. In making investment, legal, tax, or accounting decisions with respect to transactions in or for the accounts of the undersigned or any other matter, the undersigned will consult with and rely upon its own advisors and not Pershing, and Pershing shall have no liability therefore.

19. Deduction or Withholding for Tax

All payments under this agreement shall be made without any deduction or withholding for any taxes imposed by any laws, regulations, decrees, or ordinances other than U.S. state or federal laws (“Local Taxes”). The

 

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 2 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT


LoanAdvanceTM Lending Agreement

 

 

 

undersigned shall indemnify and hold Pershing harmless against any Local Taxes (including interest and penalties) levied or imposed upon Pershing (directly or by way of withholding taxes) in respect of any payment under this Agreement. The undersigned shall, upon being notified that any Local Taxes, interest, and/or penalties are owed, promptly pay to the relevant authorities the full amount required to be paid, deducted, or withheld, and cooperate fully with Pershing to the extent that any additional action or documentation is requested by Pershing or otherwise required.

The undersigned agrees that any payments and/or interest that may be owed to Pershing, shall be made net payment of any Local Taxes, interest or penalties that may be owed by the undersigned pursuant to this Agreement.

20. Extraordinary Events

Pershing shall not be liable for loss caused directly or indirectly by government restrictions, exchange or market rulings, suspension of trading, war, strikes, or other conditions beyond its control.

21. Recording Conversations

The undersigned acknowledges, understands, and agrees that for our mutual protection, Pershing may electronically record any telephone conversation between any of the undersigned and Pershing.

22. Representations as to Capacity to Enter Into Agreement

The undersigned, if an individual, represents that he or she is of full age, that unless otherwise disclosed to Pershing in writing the undersigned is not an employee of any exchange; or an employee of any corporation of which any exchange owns a majority of the capital stock; or an employee of a member firm or member corporation registered on any exchange; or an employee of a bank, trust company, or insurance company; or an employee of any corporation, firm, or individual engaged in the business of dealing either as a broker or as principal in securities, bills of exchange, acceptances, or other forms of commercial paper. The undersigned further represents that no one except the undersigned has an interest in the account or accounts of the undersigned with Pershing.

23. Joint and Several Liability

If the undersigned shall consist of more than one individual, their obligations under this agreement shall be joint and several. The undersigned have executed the Joint Account Agreement and made the election required therein. Pursuant to that agreement, Pershing may, but is not required to, accept instructions from either joint party.

24. Option Transactions

If at any time the undersigned shall enter into any transaction for the purchase or resale of an option contract, the undersigned hereby agrees to abide by the rules of any national securities association, registered securities exchange, or clearing organization applicable to the trading of option contracts and, acting alone or in concert, will not violate the position or exercise limitation rules of any such association or exchange or of the Options Clearing Corporation or other clearing organization.

25. Severability

If any provision or condition of this agreement shall be held to be invalid or unenforceable by any court, or regulatory or self-regulatory agency or body, such invalidity or unenforceability shall attach only to such provision or condition. The validity of the remaining provisions and conditions shall not be affected thereby and this agreement shall be carried out as if any such invalid or unenforceable provision or condition were not contained herein.

26. Callable Securities

Securities which are held for the account of the undersigned and which are in “street name,” or are being held by a securities depository, are commingled with the same securities being held for other clients of introducing firms and for Pershing’s own customers. The ownership of these securities by the undersigned is reflected in Pershing’s records. The undersigned has the right at any time to require delivery of any such securities that are fully paid for, or are in excess of, collateral requirements.

The terms of many bonds allow the issuer to partially redeem or “call” the issue prior to maturity date. Certain preferred stocks are also subject

to being called by the issuer. Whenever any such security being held by Pershing is partially “called,” Pershing will determine through a random selection procedure as prescribed by the New York Stock Exchange rules, the ownership of the securities to be submitted for redemption. In the event that such securities owned by the undersigned are selected and redeemed, the accounts of the undersigned will be credited with the proceeds.

In order not to be subject to this random selection process, the undersigned must instruct the Introducing Firm to have Pershing deliver the securities to the undersigned. Delivery will be effected provided, of course, that the position is unencumbered or had not already been called by the issuer as described, prior to receipt by Pershing of the instructions of the undersigned. The probability of a security being called is the same whether they are held by Pershing or by the undersigned.

27. Lost Securities

If a periodic client account statement indicates that securities were forwarded to the undersigned and the undersigned does not receive them, notify your Introducing Firm or Pershing immediately. If notification is received within 120 days after the mailing date of the securities, as reflected on the periodic statement, replacement will be made free of charge. Thereafter, a fee for replacement may apply.

28. Headings Are Descriptive

The heading of each provision hereof is for descriptive purposes only and shall not be deemed to modify or qualify any of the rights or obligations set forth in each such provision.

29. Assignment of Pershing’s Rights Under This Agreement to the Introducing Firm

The undersigned agrees that any rights that Pershing has under this agreement, including but not limited to the right to collect any debit balance or other obligations owing in any of the accounts of the undersigned, may be assigned without the undersigned’s consent or notice to the Introducing Firm of the undersigned so that the undersigned’s Introducing Firm may collect from the undersigned independently or jointly with Pershing or enforce any other rights granted to Pershing under this agreement.

30. Amendments

Pershing may amend this agreement from time to time by sending a notice of such amendment to one of the undersigned.

31. No Waiver

This agreement cannot be modified by conduct and no failure on the part of Pershing at any time to enforce its rights hereunder to the greatest extent permitted shall in any way be deemed to waive, modify, or relax all of the rights granted Pershing herein, including those rights vested in Pershing to deal with collateral on all loans advanced to me.

32. Indemnification

Without the necessity of a judicial determination, and whether or not litigation occurs, the undersigned agree to indemnify and hold harmless Pershing, undersigned’s Introducing Firm and their respective directors, officers, employees, agents and affiliates from any and all claims (whether or not meritorious), liabilities, judgments, damages, losses, costs and expenses of any nature whatsoever (including reasonable attorney’s fees and expenses) in any way related to, or arising out of or in connection with, this agreement, including without limitation, the grant by the undersigned of a first priority lien and security interest in the collateral held in the brokerage or managed account(s) and any action taken or omitted by Pershing or the undersigned’s Introducing Firm at the request of the undersigned or pursuant to instructions provided by the undersigned.

33. Entire Agreement

This agreement constitutes the full and entire understanding between the parties with respect to the provisions herein, and there are no oral or other agreements in conflict herewith. Any future modification, amendment, or supplement to this agreement or any individual provision herein can only be in the form of a writing signed by a representative of Pershing.

 

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 3 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT


LoanAdvanceTM Lending Agreement

 

 

 

34. Arbitration Disclosures

THIS AGREEMENT CONTAINS A PREDISPUTE ARBITRATION CLAUSE. BY SIGNING AN ARBITRATION AGREEMENT THE PARTIES AGREE AS FOLLOWS:

 

 

ALL PARTIES TO THIS AGREEMENT ARE GIVING UP THE RIGHT TO SUE EACH OTHER IN COURT, INCLUDING THE RIGHT TO A TRIAL BY JURY, EXCEPT AS PROVIDED BY THE RULES OF THE ARBITRATION FORUM IN WHICH A CLAIM IS FILED.

 

 

ARBITRATION AWARDS ARE GENERALLY FINAL AND BINDING; A PARTY’S ABILITY TO HAVE A COURT REVERSE OR MODIFY AN ARBITRATION AWARD IS VERY LIMITED.

 

 

THE ABILITY OF THE PARTIES TO OBTAIN DOCUMENTS, WITNESS STATEMENTS AND OTHER DISCOVERY IS GENERALLY MORE LIMITED IN ARBITRATION THAN IN COURT PROCEEDINGS.

 

 

THE ARBITRATORS DO NOT HAVE TO EXPLAIN THE REASON(S) FOR THEIR AWARD, UNLESS, IN AN ELIGIBLE CASE, A JOINT REQUEST FOR AN EXPLAINED DECISION HAS BEEN SUBMITTED BY ALL PARTIES TO THE PANEL AT LEAST 20 DAYS PRIOR TO THE FIRST SCHEDULED HEARING DATE.

 

 

THE PANEL OF ARBITRATORS WILL TYPICALLY INCLUDE A MINORITY OF ARBITRATORS WHO WERE OR ARE AFFILIATED WITH THE SECURITIES INDUSTRY.

 

 

THE RULES OF SOME ARBITRATION FORUMS MAY IMPOSE TIME LIMITS FOR BRINGING A CLAIM IN ARBITRATION. IN SOME CASES, A CLAIM THAT IS INELIGIBLE FOR ARBITRATION MAY BE BROUGHT IN COURT.

 

 

THE RULES OF THE ARBITRATION FORUM IN WHICH THE CLAIM IS FILED, AND ANY AMENDMENTS THERETO, SHALL BE INCORPORATED INTO THIS AGREEMENT.

35. Arbitration Agreement

ANY CONTROVERSY BETWEEN YOU AND US SHALL BE SUBMITTED TO ARBITRATION BEFORE AND ONLY BEFORE THE FINANCIAL INDUSTRY REGULATORY AUTHORITY.

NO PERSON SHALL BRING A PUTATIVE OR CERTIFIED CLASS ACTION TO ARBITRATION, NOR SEEK TO ENFORCE ANY PREDISPUTE ARBITRATION AGREEMENT AGAINST ANY PERSON WHO HAS INITIATED IN COURT A PUTATIVE CLASS ACTION; OR WHO IS A MEMBER OF A PUTATIVE CLASS WHO HAS NOT OPTED OUT OF THE CLASS WITH RESPECT TO ANY CLAIMS ENCOMPASSED BY THE PUTATIVE CLASS ACTION UNTIL; (I) THE CLASS CERTIFICATION IS DENIED; (II) THE CLASS IS DECERTIFIED; OR (III) THE CUSTOMER IS EXCLUDED FROM THE CLASS BY THE COURT. SUCH FORBEARANCE TO ENFORCE AN AGREEMENT TO ARBITRATE SHALL NOT CONSTITUTE A WAIVER OF ANY RIGHTS UNDER THIS AGREEMENT EXCEPT TO THE EXTENT STATED HEREIN.

36. The Laws of the State of New York Govern

This agreement and its enforcement shall be governed by the laws of the state of New York without giving effect to its conflicts of laws provisions.

37. Loan Consent and Voting Rights

By signing this agreement, the undersigned acknowledges that securities held in a brokerage or managed account(s) being used as collateral may be loaned to Pershing or loaned out to others and as permitted by law, certain securities in the undersigned’s account may be used for, among other things, settling short sales and lending the securities for short sales, and as a result, Pershing and the undersigned’s Introducing Firm may receive compensation in connection therewith. In the event the undersigned’s securities have been loaned by Pershing on the record date of a shareholder vote involving those securities, the undersigned agrees that the undersigned’s vote may be reduced to reflect the total amount of the undersigned’s securities loaned by Pershing.

38. Other Disclosures

Consumer Purposes Disclosure: Oral agreements or commitments to loan money, extend credit or to forbear from enforcing repayment of a

debt including promises to extend or renew such debt are not enforceable, regardless of the legal theory upon which it is based that is in any way related to the credit agreement. To protect you (borrower[s]) and us (creditor) from misunderstanding or disappointment, any agreements we reach covering such matters are contained in this writing, which is the complete and exclusive statement of the agreement between us, except as we may later agree in writing to modify it.

LoanAdvance Disclosure Statement

The LoanAdvance Disclosure Statement is intended to provide some basic facts about LoanAdvance accounts and to alert you to the risks involved. Before opening a LoanAdvance account, it is important to carefully review the Lending Agreement, Form T–4, Control Stock Disclosure and LoanAdvance Interest Rate Form, and the LoanAdvance Checkwriting Application (if applicable) provided by your financial organization or its clearing firm, Pershing LLC (“Pershing”), and to consult with your financial organization regarding any questions or concerns you may have regarding LoanAdvance accounts.

If you choose to borrow funds from your financial organization or Pershing, you will need to open a LoanAdvance account. The securities held in your brokerage or managed account(s) are used as collateral for the loan that was made to you. If the securities in your brokerage or managed account(s) being used as collateral decline in value, so does the value of the collateral supporting your loan. As a result, your financial organization or Pershing can take action. For instance, your financial organization or Pershing can issue a call and/or sell securities or liquidate other assets in any of your brokerage accounts held with your financial organization or Pershing in order to maintain the required equity in the collateral account(s).

It is important that you fully understand the risks involved in utilizing a LoanAdvance line-of-credit. These risks include the following:

Your financial organization or Pershing can force the sale of securities or other assets in your account(s).

If the equity in your brokerage or managed account(s) being used as collateral falls below the maintenance requirements or your financial organization’s higher “house” requirements, your financial organization or Pershing can sell the securities or other assets in any of your accounts held at your financial organization to cover the deficiency. You also will be responsible for any short fall in the account after such a sale.

Your financial organization or Pershing can sell your securities or other assets without contacting you.

Some investors mistakenly believe that a financial organization must contact them for a call to be valid, and that the financial organization cannot liquidate securities or other assets in their accounts to meet the call unless the financial organization has contacted them first. This is not the case. Most financial organizations will attempt to notify their clients of calls, but they are not required to do so. However, even if a financial organization has contacted a client and provided a specific date by which the client can meet a call, the financial organization can still take necessary steps to protect its financial interests, including immediately selling the securities without notice to the client.

Your financial organization or Pershing may change LoanAdvance requirements or account maintenance call time periods without notice to you.

In regard to house, maintenance, and other account calls, in lieu of immediate liquidations, Pershing, through your financial organization, may permit you a period of time to satisfy a call. This time period shall not in any way waive or diminish Pershing’s right in its sole discretion, to shorten the time period in which you may satisfy a call, including one already outstanding, or to demand that a call be satisfied immediately. Nor does such practice waive or diminish the right of Pershing and/or your financial organization to sell out positions to satisfy the call, which can be as high as the full indebtedness owed by you. LoanAdvance requirements may be established and changed by Pershing or your financial organization in its sole discretion and judgement.

 

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 4 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT


LoanAdvanceTM Lending Agreement

 

 

 

You are not entitled to choose which securities or other assets in your brokerage or managed account(s) are liquidated or sold to meet a call.

Because the securities are collateral for the LoanAdvance line-of-credit, your financial organization or Pershing has the right to decide which security to sell in order to protect its interests.

Your financial organization or Pershing can increase its “house” maintenance requirements at any time and is not required to provide you with advance written notice.

These changes in firm policy often take effect immediately and may result in the issuance of a maintenance call. Your failure to satisfy the call may cause your financial organization or Pershing to liquidate or sell securities in your brokerage or managed account(s).

You are not entitled to an extension of time on a call.

While an extension of time to meet call requirements may be available to clients under certain conditions, a client does not have a right to the extension.

You will be charged interest based on the Base Rate.

The Base Rate, as defined in the LoanAdvance Interest Rate Form, will change without prior notice. When the Base Rate changes during an interest period, interest will be calculated according to the number of days each rate is in effect during that period. Regardless of the underlying Base Rate, interest charged in any credit extended in a LoanAdvance account may never exceed a rate equal to 3 percentage points above the Prime Rate as published in The Wall Street Journal.

Your interest period begins on the 20th of each month and ends on the 19th of the following month.

The interest charges for the period as shown on the monthly or quarterly statement are based only on the daily net debit balances for the interest period.

Your monthly interest charge will be calculated according to the following computation:

At the close of each interest period during which credit was extended in a LoanAdvance account, an interest charge is computed by multiplying the average daily debit balance by the applicable schedule rate, and then by the number of days during which a debit balance was outstanding,

and finally dividing by 360. If there has been a change in the Base Rate, separate computations will be made with respect to each rate of charge for the appropriate number of days at each rate during the interest period. The interest charge for credit made to a LoanAdvance account at the close of the interest period is added to the opening debit balance for the next interest period unless paid.

Your written LoanAdvance Agreement with Pershing or your financial organization provides for certain important obligations by you.

The LoanAdvance Agreement is a legally binding agreement, cannot be modified by conduct, and no failure on the part of Pershing or your financial organization at any time to enforce its rights under the LoanAdvance Agreement to the greatest extent permitted shall in any way be deemed to waive, modify, or relax any of the rights granted Pershing or your financial organization, including those rights vested in Pershing or your financial organization to deal with collateral on all loans advanced to you.

Also, the LoanAdvance Agreement constitutes the full and entire understanding between the parties with respect to the provision of the LoanAdvance Agreement, and there are no oral or other agreements in conflict with the LoanAdvance Agreement unless you have advised in writing to Pershing or your financial organization of such conflict Any future modification amendment, or supplement to the LoanAdvance Agreement or any individual provision of the LoanAdvance Agreement can only be in writing signed by a representative of Pershing. You should carefully review your LoanAdvance Agreement for the rights and limitations governing your LoanAdvance and collateral account relationship(s).

If Article 15 of the EU Securities Financing Transactions Regulation (“SFTR”) is applicable to you:

Please refer to https://www.pershing.com/_global-assets/pdf/ disclosures/per-eu-article-15-info-stmt.pdf for access to an information statement disclosing the risks and consequences of delivering non-cash collateral under a relevant collateral arrangement with Pershing LLC (including a margin account). This statement does not amend or supersede the express terms of any transaction, collateral arrangement or otherwise affect your or our liabilities or obligations. Please contact your financial professional if you have any questions.

 

 

 

 LOANADVANCE LENDING AGREEMENT ACKNOWLEDGEMENT

   

BY SIGNING THIS ACKNOWLEDGEMENT FORM, I ACCEPT THE TERMS OF THE AGREEMENT, AND:

 

 

Acknowledge that I have read and understood the LoanAdvance Disclosure Statement, attached hereto, which details the risks associated with a LoanAdvance account, and have read and understood the credit terms explained in the LoanAdvance Interest Rate Form.

 

 

Acknowledge that any loan from the LoanAdvance account will not be deposited into any brokerage account.

 

 

Acknowledge that any loan from the LoanAdvance account will not be used for the purpose of: (1) purchasing or trading securities; (2) to meet margin calls relating to securities purchases; or (3) for reducing or retiring indebtedness incurred to purchase, carry, or trade securities.

 

 

Acknowledge that Pershing may require a new T4 when the loan is increased, additional collateral accounts are added or when other changes are requested.

 

Acknowledge that the initial interest rate being assessed on the undersigned’s credit line balance and the method of computation of interest have been disclosed to me in writing.

 

 

Acknowledge receipt of the LoanAdvance Interest Rate Form, which explains the annual rate of interest that can be charged to my account, how debit balances are determined, and the methods of computing interest.

 

 

Acknowledge that Pershing may compensate my Introducing Firm for its role in the establishment and maintenance of this account.

 

 

ACKNOWLEDGE THAT SECURITIES HELD IN YOUR BROKERAGE OR MANAGED ACCOUNT(S) BEING USED AS COLLATERAL MAY BE LOANED TO PERSHING OR LOANED OUT TO OTHERS.

 

 

Acknowledge receiving a copy of the LoanAdvance Lending Agreement which contains a predispute arbitration clause in paragraphs 34 and 35 above.

 

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 5 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT


LoanAdvanceTM Lending Agreement

 

 

 

STEP 1. ACCOUNT INFORMATION

    

 

 Non-Purpose Loan Account Number

 3ZT-047968

 

STEP 2. NAICS CODE

    

All new non-purpose loan accounts to an entity such as a Corporate, Partnership, Non-Profit Organization or Limited Liability Corporation account requires a six digit NAICS industry code. A complete list of NAICS is available at: https://www.naics.com/naics-drilldown-table/

Please visit this Federal Government website to determine the appropriate code for your entity and provide NAIC information below.

 

North American Industry Description

  

North American Industry Code (six digit)

      541714

 

STEP 3. SIGNATURES

    

Please be sure that all account owners sign this agreement and acknowledgement form. Caution — it is important that you thoroughly read the contract before you sign it.

 

Primary Account Owner

 

  

Print Name

  

Date

PLUS THERAPEUTICS, INC.    04-05-2024

Signature

    

/s/ ANDREW SIMS

    

Additional Account Owner

 

  

Print Name

  

Date

ANDREW SIMS    04-05-2024

Signature

    

/s/ ANDREW SIMS

    

Additional Account Owner

 

  

Print Name

  

Date

MARC HEDRICK    04-05-2024

Signature

    

/s/ MARK HEDRICK

    

Please Complete if a Trust, Corporation, Partnership, or Other Entity

 

  

Print Name of Entity

 

  

Date

Title

 

    

Signature

    

X

    

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 6 OF 6

ECAGR-LA-08-21

FORM GENERATED ON:04/05/2024 - 11:15AM EDT

Exhibit 10.2

LoanAdvanceTM Interest Rate Form

 

 

 

 

 STEP 1. ACCOUNT INFORMATION 

    

 

 

Non-Purpose Loan Account Number

3ZT047968

 

 

 STEP 2. INTEREST RATE ACKNOWLEDGEMENT 

    

The undersigned (“Borrower”) has executed a LoanAdvance Lending Agreement (the “Agreement”) with Pershing LLC (“Pershing”). Pursuant to which Borrower has access to a line of credit collateralized by the value of securities held in Borrower’s brokerage or separately managed account pledged by the Borrower (the “Account”). The Account is carried by Pershing as clearing broker pursuant to a clearing agreement between Pershing and your introducing firm. This Interest Rate Acknowledgement Form constitutes a supplement to the Agreement and shall be subject to and interpreted in accordance with the terms and conditions thereof.

The rate of interest charged on any credit extended in the Account is a floating rate based on the Base Rate* and may fluctuate over time. In addition, if your rate is based on the interest rate schedule provided by your financial organization, the rate may be higher or lower in the future depending on the aggregate outstanding loan amount, and any such change may be made without prior notice to Borrower. All rates described herein may be changed without prior notice to Borrower. In accordance with Paragraph 10 of the Agreement, regardless of the underlying Base Rate, interest charged in any credit extended in a LoanAdvance account may never exceed a rate equal to 3 percentage points above the Prime Rate as published in The Wall Street Journal.

 

 

 STEP 3. INTEREST RATE 

    

Subject to the foregoing, the rate of interest that will be charged on any credit extended in the Account is equal to:

 

SELECT ONE         BASE RATE*            +/-(SELECT ONE)    SPREAD        TOTAL RATE     

LOGO

  

Federal Funds Target (Upper Limit)

   5.50   %     

LOGO  Plus

  

LOGO  Minus

   1.75    =     7.25    %
        

 

            

 

    

 

  

LOGO

  

Prime

        %     

LOGO Plus

  

LOGO Minus

     =       %
        

 

            

 

    

 

  

LOGO

  

Other:

        %     

LOGO Plus

  

LOGO Minus

     =       %
     

 

  

 

            

 

    

 

  

LOGO

  

Interest Rate Schedule Provided by my Financial Organization

                    

*Base Rate is determined by your financial organization and may be based on Fed Funds Target, Prime Rate as published in The Wall Street Journal or another benchmark and may fluctuate over time.

 

 

 STEP 4. RESTRICTED/CONTROL STOCK DISCLOSURE 

    

 

1.   

Is the undersigned a control person of any publicly held organization?

  

LOGO

  

Yes 

  

LOGO

  

No

2.   

Are any of the shares subject to a control provision?

  

LOGO

  

Yes

  

LOGO

  

No

If you answered yes to question 2 above, please provide details below:

 

     
NUMBER OF SHARES     NAME OF COMPANY    SYMBOL

         

         

         

         

 

LOGO

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 1 OF 2

FRM-LA-DIS-ACK-10-21


LoanAdvance Interest Rate Form

  

Non-Purpose Loan Account Number 3ZT047968

 

 

 

 

 STEP 5. SIGNATURES 

    

By signing below, Borrower acknowledges receipt of a completed copy of this Form, as well as any tiered interest rate schedule, if applicable. Borrower further acknowledges their understanding and acceptance of the terms disclosed herein and attests to the accuracy of the information provided.

 

Primary Account Owner

  
   

Print Name

  

Date

ANDREW SIMS    05-24-2024
   

Signature

    

/s/ ANDREW SIMS

    

Additional Account Owner

  
   

Print Name

  

Date

MARC HEDRICK    05-24-2024
   

Signature

    

/s/ MARC HEDRICK

    

Additional Account Owner

  
   

Print Name

  

Date

  
   

Signature

    

X

    

Please Complete if a Trust, Corporation, Partnership, or Other Entity

  
   

Print Name of Entity

PLUS THERAPEUTICS INC

  

Date

05-24-2024

   

Title

CFO

    
   

Signature

    

/s/ ANDREW SIMS

    

 

 

 FOR BROKER-DEALER USE ONLY 

    

The information below must be submitted for all LoanAdvance accounts, regardless of which interest rate index is selected. In addition, by signing below, the Branch Manager acknowledges that they have provided the Borrower with the Broker-Dealers tiered interest rate schedule, if applicable.

 

 

Print Branch Manager Name

  

 

Date

  
   

Signature

    

X

    

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 2 OF 2

FRM-LA-DIS-ACK-10-21

Exhibit 10.3

Statement of Purpose for an Extension

of Credit by a Creditor  (Federal Reserve Form T–4)

 

 

 

 

Name of Creditor: Pershing LLC • OMB No. 7100-0019 • Approval expires June 30, 2024

 

This form is required by law (15 U.S.C. 78g and 78w; 12 CFR 220).

The Federal Reserve may not conduct or sponsor, and an organization (or a person) is not required to respond to, a collection of information unless it displays a currently valid OMB control number.

Public reporting burden for this collection of information is estimated to average 10 minutes per response, including the time to gather and maintain data in the required form and to review instructions and complete the information collection.

 

Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Secretary, Board of Governors of the Federal Reserve System, 20th and C Streets, N.W., Washington, DC 20551; and to the Office of Management and Budget, Paperwork Reduction Project (7100-0019), Washington, DC 20503.

 

 

 

Instructions

This form must be completed only if the purpose of the credit being extended is not to purchase, carry, or trade in securities and the credit is in excess of that otherwise permitted under Regulation T. (See § 220.6(e)(2)). If space is inadequate, attach separate sheet.

 

 

 PART I  

    

Step 1. Account Information

 

 

Non-Purpose Loan Account Number

3ZT047968

 

Step 2. To be Completed by the Customer(s)

LOGO    New loan. Amount of the credit being requested $                                       

LOGO    Non-purpose loan transfer (if applicable)

LOGO    Pershing delivering non-purpose loan account                                      

LOGO    External delivering firm name                                             

LOGO  Credit line increase. New credit line amount $3,300,000.00                                 
Purpose of credit  
The purpose of the credit is described in details as follows

LOGO    Liquidity/Expenses

 

LOGO    Other                                              

Delivery

Are any of the securities listed in Part II to be delivered, or have any such securities been delivered from a bank, broker, dealer, or other person on a “delivery against payment” basis?

LOGO  Yes  LOGO  No

 

LOGO

 

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

 

PAGE 1 OF 3

FRM-LA-T4-08-21


Statement of Purpose for an Extension of

Credit by a Creditor (Federal Reserve  Form T–4)

   Non-Purpose Loan Account Number    3ZT047968

Step 3. Signature(s)

I (We) have read this form and certify that to the best of my (our) knowledge and belief the information given is true, accurate, and complete. Unless otherwise noted in the respective section on page two, the collateral supporting the extension of credit is maintained in the brokerage account referenced above. The borrower acknowledges that no part of this credit will be used to purchase, carry, or trade in securities.

This form should not be signed if blank. A borrower who falsely certifies the purpose of a credit on this form or otherwise willfully or intentionally evades the provisions of Regulation T will also violate Federal Reserve Regulation X, “Borrowers of Securities Credit.”

 

Primary Account Owner

 

    

Print Name

  

Date

 ANDREW SIMS

  

05-29-2024

Signature

/s/ Andrew Sims

    

Additional Account Owner

 

    

Print Name

  

Date

MARC HEDRICK

  

05-29-2024

Signature

/s/ Marc Hedrick

    

Additional Account Owner

 

    

Print Name

 

  

Date

Signature

X

    

Please Complete if a Trust, Corporation, Partnership, or Other Entity

 

    

Print Name of Entity

  

Date

PLUS THERAPEUTICS INC

  

05-29-2024

Title

    

CFO

    

Signature

/s/ Andrew Sims

    

 

 

© 2021 Pershing LLC. Pershing LLC, member FINRA, NYSE, SIPC, is a wholly owned subsidiary of

   PAGE 2 OF 3

The Bank of New York Mellon Corporation (BNY Mellon). Trademark(s) belong to their respective owners.

   FRM-LA-T4-08-21
v3.24.1.1.u2
Document and Entity Information
May 31, 2024
Cover [Abstract]  
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001095981
Document Type 8-K
Document Period End Date May 31, 2024
Entity Registrant Name PLUS THERAPEUTICS, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-34375
Entity Tax Identification Number 33-0827593
Entity Address, Address Line One 4200 Marathon Blvd.
Entity Address, Address Line Two Suite 200
Entity Address, City or Town Austin
Entity Address, State or Province TX
Entity Address, Postal Zip Code 78756
City Area Code (737)
Local Phone Number 255-7194
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol PSTV
Entity Emerging Growth Company false

Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
Von Mai 2024 bis Jun 2024 Click Here for more Plus Therapeutics Charts.
Plus Therapeutics (NASDAQ:PSTV)
Historical Stock Chart
Von Jun 2023 bis Jun 2024 Click Here for more Plus Therapeutics Charts.